9d (edited) • 🍏 Nutrition Questions
Skool Member Question (Cholesterol)
Skool Member Question: When lower carbs are eaten, my cholesterol goes up. Even if I stay lower saturated fat, lower carb makes it shoot up. Everyone freaks out, and I’m never certain if I should also freak out.
What becomes very clear, once you step back and look at cholesterol through a true systems biology lens, is that not all elevations are created equal; what we casually call “high cholesterol” is not a single condition, but a collection of distinct physiological states, each driven by a different mechanism, each requiring a different intervention, and each easily misinterpreted if we rely on a single marker like low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC). At the highest level, these states fall into four primary buckets: mobilization (cholesterol is being moved), clearance defects (cholesterol cannot be removed efficiently), overproduction (cholesterol particles are being produced in excess), and genetic risk amplification (cholesterol becomes more dangerous independent of its quantity); layered across all of this, in certain individuals, is a fifth modifier, Saturated Fatty Acid Hyper-Reactivity Disorder (SFAHD), where dietary saturated fat disproportionately amplifies lipid and inflammatory signaling. If you do not identify which of these you are dealing with, you are not treating physiology; you are reacting to numbers.
The first category, and the one most relevant during active weight loss, is mobilization; this is where lipolysis is increased, often in the setting of carbohydrate reduction across a spectrum of dietary patterns (Mediterranean, Paleo, Atkins, Keto, Carnivore, whether <150g, <100g, <50g, or <20g), where the body shifts from reliance on incoming glucose to stored energy. As adipocytes release triglycerides, they also release cholesterol; the largest storage depot of cholesterol in the body is not the liver, but the fat cell itself. So when you begin “emptying the warehouse,” you are not just moving out fuel—you are moving out packaging material as well; blood cholesterol rises not because something is broken, but because something is finally moving. This is the “cleaning out the storage unit” analogy, where everything that was hidden is now in the parking lot, and it looks worse before it looks better. A more extreme expression of this exists in the Lean Mass Hyper-Responder (LMHR) phenotype, where lean, insulin-sensitive individuals exhibit very high LDL-C alongside low triglycerides and high HDL; here, the system is not congested—it is operating at high speed, with lipid particles constantly trafficking energy, unloading triglycerides, and returning cholesterol-enriched. This is not a traffic jam; it is a high-speed logistics network. Clinically, the question is not panic, but context; ApoB, LDL-P, and longitudinal markers (like CAC) determine whether this is benign adaptation or emerging risk.
The second category is clearance defects, where cholesterol is present, but the body cannot remove it efficiently. In Familial Hypercholesterolemia (FH), this is due to defects in LDL receptor function (LDLR, ApoB, PCSK9 variants); the liver cannot adequately clear LDL particles, so they accumulate regardless of dietary quality. The analogy is simple: the garbage trucks are running, but the landfill is closed; waste piles up in the streets. In this population, diet becomes a tool to reduce incoming particle burden (lower saturated fat, increase soluble fiber, incorporate plant sterols), but often this is not sufficient, and pharmacotherapy is necessary. A more subtle, but clinically common, version occurs in hypothyroidism, where thyroid hormone regulates LDL receptor expression; when thyroid signaling is low, clearance slows. The recycling center is still there, but it has lost power; material backs up. Another layer is cholestasis or impaired bile flow, including post-cholecystectomy physiology, where cholesterol cannot be effectively excreted; this becomes a drainage problem—if the pipes are clogged, you do not stop producing waste, you get backflow. Here, diet shifts toward supporting bile dynamics (meal timing, moderate fat distribution, bitter compounds, fiber), not just reducing fat indiscriminately.
The third category is overproduction, most commonly seen in insulin resistance, type 2 diabetes, and hypertriglyceridemia-driven states; here, the liver is overproducing VLDL particles due to chronic hyperinsulinemia, excess fructose, or alcohol exposure. These triglyceride-rich particles are remodeled into small, dense LDL (Pattern B), which are more atherogenic due to their ability to penetrate and adhere to the arterial wall. Instead of a few large, stable boats (Pattern A), you now have thousands of small jet skis (Pattern B) crashing into the shoreline repeatedly; the problem is not just cholesterol—it is particle behavior and frequency of impact. In this context, dietary intervention is profoundly effective; reducing glycemic load, restoring insulin sensitivity, removing ultra-processed foods, and normalizing hepatic signaling often improves the entire lipid profile, even if LDL-C appears unchanged or slightly elevated. Layered into this is chronic inflammation (TLR4, NF-κB activation), whether driven by diet, gut dysfunction, or autoimmune processes; LDL is not inherently dangerous, but in an inflamed system, it becomes problematic—like driving through a construction zone filled with debris, where damage becomes more likely.
The fourth category is genetic risk amplification, where the number of particles alone does not fully define risk because the particles themselves behave differently. Lipoprotein(a), or Lp(a), is the prime example; it is largely genetically determined and minimally responsive to diet, yet profoundly atherogenic due to its pro-inflammatory and pro-thrombotic properties. If LDL is a delivery truck, Lp(a) is a delivery truck wrapped in barbed wire; it doesn’t just deliver cargo—it injures the arterial wall. Similarly, individuals with the ApoE4 genotype exhibit altered lipid trafficking and increased sensitivity to saturated fat; the system still functions, but routing inefficiencies lead to buildup and congestion. In these populations, diet is used to reduce overall ApoB burden, minimize excessive saturated fat exposure, emphasize monounsaturated fats and omega-3s, and reduce inflammation; while the genetic signal cannot be changed, the environment in which it operates can be optimized.
Now layered across all four of these categories is Saturated Fatty Acid Hyper-Reactivity Disorder (SFAHD); not a universal condition, but a phenotype where saturated fat intake triggers a disproportionate lipid and inflammatory response. Mechanistically, saturated fatty acids (particularly lauric, myristic, and palmitic acids) can activate Toll-Like Receptor 4 (TLR4), initiating the NF-κB pathway, increasing inflammatory cytokine production, and altering hepatic lipid metabolism; in susceptible individuals, this leads to increased ApoB-containing particle production and elevated LDL-C that is not simply a function of lipolysis or energy mobilization. The analogy holds: TLR4 is the switch; NF-κB is the machinery; cytokines are the smog—and when too many machines are running, the city becomes polluted. This phenotype is particularly relevant in individuals with FH, ApoE4, insulin resistance, or underlying inflammatory conditions, where saturated fat acts as an amplifier rather than a neutral fuel. Here, dietary strategy shifts intentionally; reducing saturated fat (especially from processed sources), balancing omega-6 and omega-3 intake, emphasizing lean proteins and monounsaturated fats, and addressing gut microbiota influences on bile acid metabolism—because the issue is not just cholesterol movement, but how the system responds to specific inputs.
When you integrate all of this, the framework becomes precise: sometimes cholesterol is elevated because it is being mobilized (weight loss, LMHR); sometimes because it cannot be cleared (FH, hypothyroidism, cholestasis); sometimes because it is being overproduced (insulin resistance, hepatic overload); sometimes because it is inherently more dangerous (Lp(a), ApoE4); and sometimes because the system is hyper-reactive to specific dietary inputs (SFAHD). If you treat all of these the same, you will mismanage most of them.
So the clinical question is not, “Is this diet raising cholesterol?” That question is too blunt to be useful. The real question is: what is the system doing with cholesterol right now—is it moving it, failing to clear it, overproducing it, amplifying risk, or overreacting to specific dietary signals? Once you answer that, the dietary intervention becomes obvious; and this is the shift from generic nutrition advice to true clinical nutrition strategy, where diet is no longer a philosophy, but a precision tool aligned with physiology :)
3
12 comments
Skool Member Question (Cholesterol)
Leaderboard (30-day)
1
+137
2
+67
3
+60
4
+9
5
+4
Powered by